{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-15T05:12:17.253742+00:00","company":{"ticker":"BIVI","cik":1580149,"company_name":"BIOVIE INC."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"ThinkEquity LLC","detail":"equity_purchase","count":1,"first_seen":"2024-03-04T23:59:59+00:00","last_seen":"2024-03-04T23:59:59+00:00","evidence_fact_ids":[69964]}]},"facts":[{"fact_type":"executive_change","fact_key":"a733556ac6","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2025-03-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Robert Hariri resigned as Director at BIOVIE INC..","evidence_excerpt":"On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001520138-25-000089","anchor_url":"https://secwatch.observer/filing/0001520138-25-000089#claim-a733556ac6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013825000089/0001520138-25-000089-index.htm"},{"fact_type":"executive_change","fact_key":"05dad22d8b","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2024-07-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-25","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Steve Gorlin resigned as Director at BIOVIE INC..","evidence_excerpt":"On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001520138-24-000251","anchor_url":"https://secwatch.observer/filing/0001520138-24-000251#claim-05dad22d8b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000251/0001520138-24-000251-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e2c6bab26b7697c5f68e1892f6e35afc8936d877","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2024-04-19T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-10-15","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-04-18","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"BIOVIE INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 18, 2024, BioVie Inc.\n(the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days\nhad closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under\nNasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until October 15, 2024, to regain\ncompliance with the minimum bid price requirement. The continued listing standard will","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001520138-24-000179","anchor_url":"https://secwatch.observer/filing/0001520138-24-000179#claim-e2c6bab26b7697c5f68e1892f6e35afc8936d877","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000179/0001520138-24-000179-index.htm"},{"fact_type":"material_agreement","fact_key":"da33a6d72caa6379d82abf3de02f7f047fecda9e","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2024-03-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"equity_purchase","counterparty":"ThinkEquity LLC","effective_date":"2024-03-04","item_codes_triggered":["1.01"],"value_text":"approximately $21,000,000 million"},"claim":"BIOVIE INC. entered into Agreement with ThinkEquity LLC valued at approximately $21,000,000 million (effective 2024-03-04).","evidence_excerpt":"On March 4, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 21,000,000 shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001520138-24-000086","anchor_url":"https://secwatch.observer/filing/0001520138-24-000086#claim-da33a6d72caa6379d82abf3de02f7f047fecda9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000086/0001520138-24-000086-index.htm"},{"fact_type":"shareholder_vote","fact_key":"88213ef52bceef486587fd4e3e195f9c25256383","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-08","outcome":"passed","proposal_text":"Approval and Ratification of Auditors","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"4,528,595","subject":null,"votes_abstain":"19,155","votes_against":"180,567","votes_for":"29,275,023","votes_withheld":null}]},"claim":"BIOVIE INC. shareholders approved Approval and Ratification of Auditors at the 2023-11-08 meeting.","evidence_excerpt":"Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the 2024 fiscal year. The voting results were as follows: For Against Abstain Broker Non-Vote 29,275,023 180,567 19,155 4,528,595","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001520138-23-000488","anchor_url":"https://secwatch.observer/filing/0001520138-23-000488#claim-88213ef52bceef486587fd4e3e195f9c25256383","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013823000488/0001520138-23-000488-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1abbe213beb68b3f0d3692eb18d1d7bec730c957","cik":1580149,"ticker":"BIVI","company_name":"BIOVIE INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-08","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,528,595","subject":"CUONG DO","votes_abstain":null,"votes_against":null,"votes_for":"24,871,797","votes_withheld":"74,353"},{"broker_non_votes":"4,528,595","subject":"JIM LANG","votes_abstain":null,"votes_against":null,"votes_for":"24,557,658","votes_withheld":"388,492"},{"broker_non_votes":"4,528,595","subject":"MICHAEL SHERMAN","votes_abstain":null,"votes_against":null,"votes_for":"24,630,002","votes_withheld":"316,148"},{"broker_non_votes":"4,528,595","subject":"RICHARD J. BERMAN","votes_abstain":null,"votes_against":null,"votes_for":"24,526,699","votes_withheld":"419,451"},{"broker_non_votes":"4,528,595","subject":"STEVE GORLIN","votes_abstain":null,"votes_against":null,"votes_for":"24,602,592","votes_withheld":"343,558"},{"broker_non_votes":"4,528,595","subject":"ROBERT HARIRI, M.D. PHD","votes_abstain":null,"votes_against":null,"votes_for":"24,774,046","votes_withheld":"172,104"},{"broker_non_votes":"4,528,595","subject":"SIGMUND ROGICH","votes_abstain":null,"votes_against":null,"votes_for":"24,867,955","votes_withheld":"78,195"}]},"claim":"BIOVIE INC. shareholders approved Election of Directors at the 2023-11-08 meeting.","evidence_excerpt":"Stockholders elected all of the Company’s nominees for director for one-year terms expiring at the next annual meeting of stockholders upon election and qualification of their successors. The voting results were as follows: For Withhold Broker Non-Vote (1) CUONG DO 24,871,797 74,353 4,528,595 (2) JIM LANG 24,557,658 388,492 4,528,595 (3) MICHAEL SHERMAN 24,630,002 316,148 4,528,595 (4) RICHARD J. BERMAN 24,526,699 419,451 4,528,595 (5) STEVE GORLIN 24,602,592 343,558 4,528,595 (6) ROBERT HARIRI, M.D. PHD 24,774,046 172,104 4,528,595 (7) SIGMUND ROGICH 24,867,955 78,195 4,528,595","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001520138-23-000488","anchor_url":"https://secwatch.observer/filing/0001520138-23-000488#claim-1abbe213beb68b3f0d3692eb18d1d7bec730c957","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013823000488/0001520138-23-000488-index.htm"}]}